ProfileGDS5678 / 1440212_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 22% 21% 22% 20% 22% 21% 21% 21% 22% 22% 21% 22% 22% 21% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.539122
GSM967853U87-EV human glioblastoma xenograft - Control 22.5033721
GSM967854U87-EV human glioblastoma xenograft - Control 32.511622
GSM967855U87-EV human glioblastoma xenograft - Control 42.4189620
GSM967856U87-EV human glioblastoma xenograft - Control 52.4608722
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.569121
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.5342821
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4851821
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4840922
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5006722
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.491721
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.482422
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5089922
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4948721